US10350274B2 - Method for the preparation of human albumin with reduced level of dissolved oxygen - Google Patents
Method for the preparation of human albumin with reduced level of dissolved oxygen Download PDFInfo
- Publication number
- US10350274B2 US10350274B2 US14/724,649 US201514724649A US10350274B2 US 10350274 B2 US10350274 B2 US 10350274B2 US 201514724649 A US201514724649 A US 201514724649A US 10350274 B2 US10350274 B2 US 10350274B2
- Authority
- US
- United States
- Prior art keywords
- albumin
- solution
- stage
- dissolved oxygen
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 239000001301 oxygen Substances 0.000 title claims abstract description 48
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 48
- 108091006905 Human Serum Albumin Proteins 0.000 title claims abstract description 24
- 102000008100 Human Serum Albumin Human genes 0.000 title claims abstract description 24
- 230000002829 reductive effect Effects 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 62
- 238000009928 pasteurization Methods 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 238000004381 surface treatment Methods 0.000 claims description 21
- 239000011261 inert gas Substances 0.000 claims description 16
- 239000001307 helium Substances 0.000 claims description 15
- 229910052734 helium Inorganic materials 0.000 claims description 15
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 15
- 230000005587 bubbling Effects 0.000 claims description 11
- 239000012298 atmosphere Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 108010004546 mercaptoalbumin Proteins 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 abstract description 136
- 108010088751 Albumins Proteins 0.000 abstract description 136
- 239000000243 solution Substances 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 13
- 230000001590 oxidative effect Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000002033 PVDF binder Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011146 sterile filtration Methods 0.000 description 5
- -1 thiol compound Chemical class 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000012859 sterile filling Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920005556 chlorobutyl Polymers 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000005184 irreversible process Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940116191 n-acetyltryptophan Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001581 pretranslational effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a method for the preparation of a solution of human albumin, more particularly it relates to a method comprising a stage of reducing the dissolved oxygen in said solution of albumin until a concentration equal to or less than 0.5 ppm.
- a solution of human albumin having a redox state closer to the redox state of the albumin present in human plasma.
- a method of preparing a solution of a human albumin includes a stage of reducing a level of dissolved oxygen in the solution, wherein the level of dissolved oxygen is reduced to a concentration equal to or less than 0.5 ppm.
- the stage of reducing the level of dissolved oxygen in the solution can be carried out by a surface treatment of the solution with an inert gas or by bubbling of an inert gas into an interior of the solution.
- the human albumin can be of any origin, such as a plasmatic recombinant origin or a transgenic origin.
- An exemplary concentration of the human albumin would be between about 4% and 25% (w/v).
- Examples of the inert gas include nitrogen or helium.
- the stage of reducing the level of dissolved oxygen in the solution is sometimes carried out prior to or subsequent to a stage of pasteurisation of the solution.
- the solution can be maintained in an inert gas atmosphere, including a gas such as nitrogen or helium, subsequent to the stage of reducing the level of dissolved oxygen in the solution.
- a gas such as nitrogen or helium
- the solution can be packed and/or stored in a container including a material impermeable to oxygen, such as glass.
- An exemplary concentration of dissolved oxygen would be equal to or less than 0.5 ppm.
- the solution can be prepared into a medicament.
- FIG. 1 shows a schematic diagram of a method for the obtainment of therapeutic human albumin from plasma utilised in the prior state of the art.
- Human albumin is a non-glycosylated protein of 66 kDa. Quantitatively, it is the most significant plasma protein and the concentration thereof in normal plasma lies between 35 and 50 g/l, constituting up to 60% of total plasmatic proteins (Peters T. J.: All About Albumin; Biochemistry, Genetics and Medical Applications. Academic Press, San Diego, 1996).
- human albumin consists of a polypeptide having 585 amino acids with about 67% alpha-helices, without beta-sheets being present (Otagiri M., Chuang V. T.: Pharmaceutically important pre- and posttranslational modifications on human serum albumin. Biol Pharm Bull 2009; 32:527-534).
- Human albumin contains methionine and 35 cysteine residues involved in the formation of 17 disulphide bonds. Cys-34 is the only free cysteine in the entire molecule.
- Human albumin has specific antioxidant functions by virtue of the capacity to bond to multiple ligands and the radical entrapment properties thereof, both closely related to the structure thereof.
- Cys-34 is a site particularly sensitive to oxidation/reduction. Consequently, in general, it is legitimate to speak of the redox state of albumin in terms of Cys-34.
- chromatographic separation of albumin three fractions are obtained, according to the redox state of Cys-34 (Peters, 1996, op. cit.):
- Albumin may undergo diverse structural modifications, both in vivo and during the methods employed to produce therapeutic albumin, resulting in the modification of the conformation thereof and, as a consequence, the bonding properties together with the redox state thereof (Oettl, K. et al, 2010, op. cit.).
- the Cohn method commences with human plasma which is subjected to successive stages of precipitation and separation. In each a precipitate enriched in one of the plasmatic proteins and a decantation supernatant is obtained.
- a precipitate enriched in one of the plasmatic proteins and a decantation supernatant is obtained.
- parameters of the solution such as, inter alia, pH, dielectric constant, temperature, protein concentration, and ionic strength.
- said Cohn fractions contain increasing concentrations of ethanol.
- the albumin contained in the supernatant of Fraction IV is precipitated with about 40% (v/v) ethanol and goes on to form part of the paste of Fraction V.
- Fraction V is obtained, the latter is resuspended in a solution and is subjected to different stages until the final product is obtained.
- these stages include: diafiltration, heat treatment, sterilisation, filling into vials, and final pasteurisation of said vials, prior to submission of said vials to quarantine, in general during a period of not less than 14 days at 30-32° C., with the objective of ensuring the sterility of the final product.
- the inventors have discovered that, by means of the addition of a stage in the process of production of a solution of human albumin comprising reducing the dissolved oxygen in the solution, wherein the level of oxygen is reduced to a concentration equal to or less than 0.5 ppm, a reduction in the oxidation of Cys-34 is achieved, there being obtained a redox state of the albumin very similar to the redox state which albumin presents in blood plasma.
- a redox state of the albumin very similar to the redox state which albumin presents in blood plasma.
- the present invention reveals a method for the preparation of a solution of human albumin characterised in that it comprises a stage of reducing the dissolved oxygen in said solution of albumin, wherein the level of oxygen is reduced to a concentration equal to or less than 0.5 ppm.
- said solution of albumin is maintained in an inert gas atmosphere.
- Said stage of reducing the dissolved oxygen in the solution of albumin may be carried out in various ways known in the state of the art.
- a surface treatment of the solution of albumin may be realised with an inert gas or an inert gas may be bubbled into the interior of said solution of albumin.
- Said inert gas used in the method of the present invention may be nitrogen, helium or similar gases.
- the method of the present invention may be utilised for the obtainment of solutions of albumin having an albumin concentration of between about 4 and 25% (w/v).
- the obtained albumin is therapeutic albumin.
- the albumin of the present invention may be albumin obtained in recombinant or transgenic form.
- the molecule of recombinant or transgenic albumin is identical to human albumin in terms of the sequence of amino acids thereof, it does not present glycosylation and, having the objective of it being functional, it must present the same conformational folding as the albumin of human plasmatic origin. Should this not be so it could not be administered to humans by virtue of the risk of immunogenicity, among other possible adverse effects caused by said differences.
- the stage of reducing the dissolved oxygen in the solution of albumin of the present invention may be carried out prior to or subsequent to a stage of pasteurisation of said solution of albumin, or moreover it may be carried out although a stage of pasteurisation of said solution of albumin is not realised, being independent of the process of preparation of the initial solution of albumin.
- said solution of albumin is maintained in an inert gas atmosphere.
- Said inert gas atmosphere may be of nitrogen, helium or similar gases.
- said container is manufactured from a material impermeable to oxygen, more preferably from glass.
- a further objective of the present invention is to reveal a composition comprising human albumin prepared by means of the method of the present invention and the use thereof as medicament.
- the present invention reveals the use of a composition comprising albumin prepared according to the hereinbefore described method for the preparation of a medicament.
- Cohn's Fraction V Human plasma obtained from healthy donors was subjected to successive stages of precipitation and separation, according to Cohn's method (Cohn E. J. et al, 1946, op. cit.), from the obtainment of the initial cryoprecipitation supernatant until achieving the precipitation of Fraction V (see FIG. 1 ).
- Cohn's Fraction V was suspended in cold water for injection (WFI), it was adjusted to pH 7.0 and was clarified by means of in-depth filters. The clarified solution was diafiltered at constant volume, applying a dialysis solution formed by a salt of monovalent ions (sodium chloride) and maintaining the temperature at 5° C. ( FIG. 1 , clarification/diafiltration stage).
- Sodium caprylate and N-acetyltryptophan were added as stabilisers to the diafiltered solution.
- Said solution was subjected to heat treatment at 60° C. ( FIG. 1 , heat-treatment stage).
- the heat-treated solution was diluted with WFI or was concentrated as a function of the desired final protein concentration desired (for example, 5%, 20% or 25% (w/v)) ( FIG. 1 , non-packed solution).
- the final solution was then filtered in a sterile manner (0.22 ⁇ m filters) and the filling of the final sterile containers was proceeded to in an aseptic zone ( FIG. 1 , sterile filtration and filling stage).
- the solution in the final container was heated at 60° C.
- FIG. 1 pasteurization in vials stage.
- FIG. 1 pasteurization in vials stage.
- the vials were incubated at 30-32° C. during not less than 14 days ( FIG. 1 , quarantine stage). Following said period, the vials were visually inspected to discard any indication of microbial contamination ( FIG. 1 , final albumin product).
- the oxidative state of the samples of albumin from different stages of the process of obtainment of the albumin was analysed by high-performance liquid chromatography (HPLC), based on the method described by Oettl K., 2010, op. cit., and as detailed below.
- the samples of albumin under study were diluted in a buffer of 0.3 M, sodium chloride, 0.1 M sodium phosphate, pH 6.87, to a concentration of 6.5 mg/ml, and 5 ⁇ l was injected into a Shodex Asahipak ES-502N DEAE anion exchange column (7.5 ⁇ 100 mm, Shodex, Japan) with a flow of 1.0 ml/min.
- the detection of the three fractions of the albumin as a function of the oxidative state thereof was carried out by means of fluorescence, utilising as excitation and emission wavelengths 280 and 340 nm, respectively.
- the quantification of the concentration of the HMA, HNA1 and HNA2 forms of Cys-34 of the albumin was carried out taking into account the height of each of the peaks of interest obtained in the corresponding chromatogram.
- FIG. 2 shows the change in the oxidative state of the samples of human serum albumin from different stages during the process of obtainment of albumin of the prior state of the art.
- the data shows an increase in the HNA1 and HNA2 forms in detriment to the HMA form, particularly subsequent to the stage of pasteurisation with subsequent quarantine (final 20% albumin product).
- the behaviour of the oxidative state of the albumin following the stages of pasteurisation and quarantine in purified 5% and 25% albumin concentration from human plasma with the method of the prior state of the art ( FIG. 3 ) is equivalent to that observed for the final 20% albumin products following the same technique ( FIG. 2 ).
- the data obtained shows an increase in the HNA1 and HNA2 forms in detriment to the HMA form, particularly following the stage of pasteurisation with subsequent quarantine.
- Example 2 Method for the Obtainment of Albumin of the Present Invention utilising a Stage of Surface Treatment with Nitrogen Prior to the Pasteurisation
- the method for the obtainment of the albumin of the present invention corresponds to the method described in Example 1, further including a stage of reducing dissolved oxygen in the solution of albumin, as is described below.
- a surface treatment with nitrogen was carried out, inserting into the chlorobutyl stopper of the vial two hypodermic needles (of the commercial type Braun Sterican 21G ⁇ 11 ⁇ 2′′, 0.80 ⁇ 40 mm, Germany, or similar) connected to two 0.22 ⁇ m PVDF filters (of the commercial type Millex GV Millipore, 0.22 ⁇ m, PVDF, 13 mm filter, USA, or similar), avoiding contact of the needles with the solution of albumin.
- One of the needles was destined as the inlet of the nitrogen gas and the other as the outlet thereof having the objective of preventing overpressure within the container.
- the treatment with surface nitrogen was carried out at room temperature for two hours, maintaining a constant flow of nitrogen having the objective of permitting observation of the movement of the liquid within the container without it splashing within the same.
- Example 1 pasteurization in vials stage
- FIG. 4 shows the results obtained, there was observed the non-decrease in the HMA form and the non-increase in the HNA1 and HNA2 forms observed in FIGS. 2 and 3 with the method for the obtainment of the albumin of the prior art.
- the employed probe whose functioning is based on the principle of the galvanic cell, comprised a silver (Ag) anode sheathed with a platinum (Pt) wire functioning as cathode.
- the aforedescribed assembly is inserted in a protective cover full of an electrolytic solution of potassium chloride which has at its extremity a membrane of Teflon®, a material permeable to the gas, permitting the passage of the oxygen present in the solution but not the passage of the solution itself.
- a potential of 790 mV the oxygen present in the cell is reduced to hydroxide ions (OH ⁇ ) at the cathode and silver chloride is deposited at the anode.
- This reaction brings about a current flow having an intensity proportional to the quantity of oxygen present in the sample.
- the meter then converts the measurement of the current flow into the corresponding concentration of dissolved oxygen.
- Example 3 Method for the Obtainment of Albumin of the Present Invention utilising a Stage of Bubbling Nitrogen into the Solution Prior to the Pasteurisation
- the method for the obtainment of the albumin of the present invention corresponds to the method described in Example 1, including the stage described below.
- the treatment of bubbling nitrogen was carried out by inserting into the chlorobutyl stopper of the vial two hypodermic needles (of the commercial type Braun Sterican 21G ⁇ 11 ⁇ 2′′, 0.80 ⁇ 40 mm, Germany, or similar) connected to two 0.22 ⁇ m PVDF filters (of the commercial type Millex GV Millipore, 0.22 ⁇ m, PVDF, 13 mm filter, USA, or similar).
- a spinal needle (of the commercial type Terumo Spinal Needle, 18G ⁇ 31 ⁇ 2′′, 1.20 ⁇ 90 mm, Japan, or similar), was submerged in the solution of albumin and the hypodermic needle (of the commercial type Braun Sterican 21G ⁇ 11 ⁇ 2′′, 0.80 ⁇ 40 mm, Germany, or similar), located avoiding contact with the liquid, was destined as the outlet thereof having the objective of preventing overpressure within the container.
- the treatment of bubbling nitrogen was carried out at room temperature for two hours, maintaining a constant flow of nitrogen having the objective of permitting observation of small bubbles within the liquid.
- the method for the obtainment of albumin from human plasma continued as described in Example 1 ( FIG. 1 , pasteurization in vials stage), until the obtainment of the final albumin product.
- the oxidative state was analysed by means of anion exchange chromatography of the samples of 20% albumin concentration obtained by the technique of the present invention. Specifically, samples of albumin subjected to a stage of bubbling nitrogen prior to the stage of pasteurisation, samples of albumin following the pasteurisation and prior to quarantine, and samples of albumin following the period of quarantine, were analysed.
- FIG. 5 shows the results obtained, these being similar to those obtained in FIG. 4 , utilising a stage of surface treatment with nitrogen prior to the pasteurisation. There was observed the non-decrease in the HMA form and the non-increase in the HNA1 and HNA2 forms observed in FIGS. 2 and 3 with the method for the obtainment of albumin of the prior art.
- Example 4 Method for the Obtainment of Albumin of the Present Invention utilising a Stage of Surface Treatment with Nitrogen Prior to the Pasteurisation, Applied to Different Final Concentrations of Albumin
- the method for the obtainment of the albumin of the present invention corresponds to the method described in Example 2, applied to other concentrations of albumin such as 5 and 25%.
- the oxidative state of the samples of 5 and 25% concentration of albumin obtained with the technique of the present invention was analysed by means of anion exchange chromatography. Specifically, samples of 5 and 25% albumin subjected to a stage of surface treatment with nitrogen prior to the pasteurisation, samples of 5 and 25% albumin subsequent to the pasteurisation and prior to quarantine, and samples of 5 and 25% albumin following the quarantine period, were analysed.
- FIG. 6 shows the results obtained, these being similar to those obtained in FIG. 4 for albumin at a concentration of 20%. There was observed the non-decrease in the HMA form and the non-increase in the HNA1 and HNA2 forms observed in FIGS. 2 and 3 with the method for the obtainment of the albumin of the prior art.
- Example 5 Method for the Obtainment of Albumin of the Present Invention utilising a Stage of Surface Treatment with Helium Prior to the Pasteurisation
- the method for the obtainment of the albumin of the present invention corresponds to the method described in Example 1, including the stage described below.
- the surface treatment with helium was carried out, inserting into the chlorobutyl stopper, and avoiding contact with the solution of albumin, two hypodermic needles (of the commercial type Braun Sterican 21G ⁇ 11 ⁇ 2′′, 0.80 ⁇ 40 mm, Germany, or similar) connected to two 0.22 ⁇ m PVDF filters (of the commercial type Millex GV Millipore, 0.22 ⁇ m, PVDF, 13 mm filter, USA, or similar), avoiding contact of the needles with the solution of albumin.
- One of the needles was destined as the inlet of the helium gas and the other as the outlet thereof having the objective of preventing overpressure within the container.
- the treatment with surface helium was carried out at room temperature for two hours, maintaining a constant flow of helium having the objective of permitting observation of the movement of the liquid within the container without it splashing within the same.
- the method for the obtainment of albumin commencing from human plasma continued as described in Example 1 ( FIG. 1 , pasteurization in vials stage), until the obtainment of the final albumin product.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201430824 | 2014-05-29 | ||
ESP201430824 | 2014-05-29 | ||
ES201430824A ES2524516B1 (es) | 2014-05-29 | 2014-05-29 | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
Publications (3)
Publication Number | Publication Date |
---|---|
US20150343025A1 US20150343025A1 (en) | 2015-12-03 |
US20170000855A9 US20170000855A9 (en) | 2017-01-05 |
US10350274B2 true US10350274B2 (en) | 2019-07-16 |
Family
ID=52003454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/724,649 Active 2035-12-13 US10350274B2 (en) | 2014-05-29 | 2015-05-28 | Method for the preparation of human albumin with reduced level of dissolved oxygen |
Country Status (22)
Country | Link |
---|---|
US (1) | US10350274B2 (zh) |
EP (1) | EP2952203B9 (zh) |
JP (3) | JP2015224251A (zh) |
KR (1) | KR101960729B1 (zh) |
CN (1) | CN105315362B (zh) |
AR (1) | AR100618A1 (zh) |
AU (1) | AU2015202413B2 (zh) |
BR (1) | BR102015012091A8 (zh) |
CA (1) | CA2890642C (zh) |
CL (1) | CL2015001446A1 (zh) |
ES (2) | ES2524516B1 (zh) |
HU (1) | HUE031823T2 (zh) |
IL (1) | IL238898B (zh) |
MX (1) | MX362869B (zh) |
MY (1) | MY171771A (zh) |
NZ (1) | NZ708537A (zh) |
PL (1) | PL2952203T3 (zh) |
PT (1) | PT2952203T (zh) |
RU (1) | RU2657578C2 (zh) |
SG (1) | SG10201504137PA (zh) |
TW (1) | TWI607018B (zh) |
ZA (1) | ZA201503539B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2524516B1 (es) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
EP3995141B1 (en) | 2016-04-28 | 2024-01-03 | Alkahest, Inc. | Plasma fractions as therapy for thymic cancer |
UA126232C2 (uk) | 2016-08-18 | 2022-09-07 | Алкахест, Інк. | Спосіб лікування когнітивного розладу, пов'язаного зі старінням, та набір, що містить фракцію плазми крові |
CA3061194A1 (en) | 2017-04-26 | 2018-11-01 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
WO2020018343A1 (en) | 2018-07-20 | 2020-01-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
CN109627322A (zh) * | 2019-01-07 | 2019-04-16 | 中国科学院过程工程研究所 | 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4094965A (en) | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
US20020192411A1 (en) | 2001-03-27 | 2002-12-19 | Toshiya Kai | Plastic container containing albumin solution |
WO2003020325A2 (en) | 2001-08-31 | 2003-03-13 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
EP1538151A1 (en) | 2003-08-28 | 2005-06-08 | Nipro Corporation | Artificial oxygen carrier and production method thereof |
US8231599B2 (en) * | 2007-11-12 | 2012-07-31 | Grifols, S.A. | Process for obtaining high efficiency human albumin for use in detoxification therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
JPH07126182A (ja) * | 1993-10-27 | 1995-05-16 | Green Cross Corp:The | 組換えヒト血清アルブミン製剤の滅菌方法 |
SE9402119D0 (sv) * | 1994-06-16 | 1994-06-16 | Pharmacia Ab | Solution |
US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
JP4254117B2 (ja) * | 2001-03-27 | 2009-04-15 | ニプロ株式会社 | アルブミン溶液収容プラスチック容器 |
JP4225416B2 (ja) * | 2001-06-29 | 2009-02-18 | 旭化成ファーマ株式会社 | タンパク質製剤の安定性を改善する方法 |
ES2391657T3 (es) * | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Composiciones estabilizadas de proteínas que tienen un resto tiol libre |
JP5990880B2 (ja) * | 2011-08-31 | 2016-09-14 | 東レ株式会社 | 有用タンパク質組成物およびその製造方法 |
CN102816230B (zh) * | 2012-08-27 | 2014-02-12 | 同路生物制药股份有限公司 | 人血白蛋白的制备方法 |
ES2524516B1 (es) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
-
2014
- 2014-05-29 ES ES201430824A patent/ES2524516B1/es not_active Expired - Fee Related
-
2015
- 2015-04-01 HU HUE15382164A patent/HUE031823T2/en unknown
- 2015-04-01 ES ES15382164.0T patent/ES2601137T3/es active Active
- 2015-04-01 EP EP15382164.0A patent/EP2952203B9/en active Active
- 2015-04-01 PT PT153821640T patent/PT2952203T/pt unknown
- 2015-04-01 PL PL15382164T patent/PL2952203T3/pl unknown
- 2015-05-01 CA CA2890642A patent/CA2890642C/en active Active
- 2015-05-06 AU AU2015202413A patent/AU2015202413B2/en active Active
- 2015-05-15 MY MYPI2015701570A patent/MY171771A/en unknown
- 2015-05-18 RU RU2015118453A patent/RU2657578C2/ru active
- 2015-05-19 IL IL238898A patent/IL238898B/en active IP Right Grant
- 2015-05-20 ZA ZA2015/03539A patent/ZA201503539B/en unknown
- 2015-05-21 MX MX2015006407A patent/MX362869B/es active IP Right Grant
- 2015-05-22 CN CN201510264800.9A patent/CN105315362B/zh active Active
- 2015-05-26 SG SG10201504137PA patent/SG10201504137PA/en unknown
- 2015-05-26 BR BR102015012091A patent/BR102015012091A8/pt not_active IP Right Cessation
- 2015-05-26 TW TW104116876A patent/TWI607018B/zh not_active IP Right Cessation
- 2015-05-27 AR ARP150101653A patent/AR100618A1/es active IP Right Grant
- 2015-05-27 NZ NZ708537A patent/NZ708537A/en not_active IP Right Cessation
- 2015-05-28 CL CL2015001446A patent/CL2015001446A1/es unknown
- 2015-05-28 US US14/724,649 patent/US10350274B2/en active Active
- 2015-05-28 JP JP2015108569A patent/JP2015224251A/ja active Pending
- 2015-05-28 KR KR1020150074568A patent/KR101960729B1/ko active IP Right Grant
-
2018
- 2018-04-27 JP JP2018086673A patent/JP2018115210A/ja active Pending
-
2020
- 2020-04-20 JP JP2020074749A patent/JP2020111614A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4094965A (en) | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
US20020192411A1 (en) | 2001-03-27 | 2002-12-19 | Toshiya Kai | Plastic container containing albumin solution |
WO2003020325A2 (en) | 2001-08-31 | 2003-03-13 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
EP1538151A1 (en) | 2003-08-28 | 2005-06-08 | Nipro Corporation | Artificial oxygen carrier and production method thereof |
US8231599B2 (en) * | 2007-11-12 | 2012-07-31 | Grifols, S.A. | Process for obtaining high efficiency human albumin for use in detoxification therapy |
Non-Patent Citations (14)
Title |
---|
Akers, M. J. & Defelippis, M. R. Peptides and proteins as parenteral solutions. En: Pharmaceutical formulation development of peptides and proteins. USA, Edited by Hovgaard, L., Frokjaer, S., van de Weert, M. Taylor & Francis Group., Second edition, 2012, Chapter 8, pp. 161-162, ISBN 978-1-4398-5388-7. |
Akers, M.J., et al. 2012 Pharmaceutical Formulation Development of Peptides and Proteins 2nd edition, Hovgaard et al., chapter 8: p. 149, 158-162. * |
Butler, I.B., et al. 1994 Talanta 41(2): 211-215. * |
Cohn E.J. et al. Preparation and properties of serum plasma proteins, IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 68, 459-475, 1946. |
Extended European Search Report dated Nov. 9, 2015 issued in European Application No. 15382164.0-1456. |
Hayashi, T. et al. The importance of sample preservation temperature for analysis of the redox state of human serum albumin. Clinica Chimica Acta. vol. 316, pp. 175-178, Feb. 2002. |
Marie, A.-L. et al. Capillary zone electrophoresis and capillary electrophoresis-mass spectrometry for analyzing qualitative and quantitative variations in therapeutic albumin. Analytica Chimica Acta. vol. 800, pp. 103-110, Oct. 2013. |
Oettl et al., "Physiological and pathological changes in the redox state of the suman serum albumin critically influence its binding properties," 2007, British Journal of Pharmacology, vol. 151, No. 5, pp. 580-590. |
Oettl K. and Marsche G. Redox State of human serum albumin in terms of cysteine-34 in health and disease. Methods Enzymol. 474:181-95, 2010. |
Oettl K. et al. Oxidative albumin damage in chronic liver failure: Relation to albumin binding capacity; liver dysfunction and survival. J Hepatol 59:978-983, 2013. |
Oettl K., et al. Oxidative damage of albumin in advanced liver disease. Biochim. Biophys. Acta 1782: 469-473, 2008. |
Otagiri M., Chuang V.T. Pharmaceutically important pre- and posttranslational modifications on human serum albumin. Biol Pharm Bull 32:527-534, 2009. |
Peters, Jr., T., "All About Albumin Biochemistry, Genetics and Medical Applications," Copyright © 1995 Elsevier Inc., ISBN: 978-0-12-552110-9 (Abstract Only). |
Search Report for ES201430824 dated Nov. 18, 2014. |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10350274B2 (en) | Method for the preparation of human albumin with reduced level of dissolved oxygen | |
KR101042660B1 (ko) | 안정한 액체 인터페론 제제 | |
JPS6267032A (ja) | 組換ヒトβ―インターフェロンを含有する医薬組成物及びその製造方法 | |
EA025663B1 (ru) | Композиции этанерцепта, стабилизированные ионами металлов | |
JP5744959B2 (ja) | 解毒療法に使用するためのヒトアルブミンを高効率で得る方法 | |
JP2002128796A (ja) | 加熱処理工程を含むヒト血清アルブミンの製造方法 | |
CN1330370C (zh) | 稳定的白蛋白制剂 | |
EP4032541A1 (en) | Preparation containing human albumin and preparation method therefor | |
JPH0733800A (ja) | 精製単量体健康人血清アルブミン(ヒト) | |
BR112020001363A2 (pt) | formulações de hemopexina | |
US20030080056A1 (en) | Extraction of biological components from body fluids | |
WO2002072135A1 (fr) | Preparations d'interferon alpha liquide pour injection et procede de stabilisation de celles-ci | |
RU2801099C1 (ru) | Препарат, содержащий человеческий альбумин, и способ его получения | |
Pollio et al. | LACTOFERRIN EFFICACY IN TREATING HYPERFERRITINEMIA IN PATIENTS SUFFERING FROM PATHOLOGIES UNRELATED TO HEREDITARY HEMOCHROMATOSIS | |
RU2391354C1 (ru) | Комплекс биологически активного рекомбинантного белка с полисиаловой кислотой | |
Akbarzadehlaleh et al. | An efficient non-chromatographic method to separate human serum albumin from cryo-poor plasma | |
CN118203658A (zh) | 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法 | |
EP4380972A1 (en) | Compositions and methods for vascular protection after myocardial ischemia | |
JP2012532167A (ja) | インターフェロンβの精製方法 | |
CN1700928A (zh) | 用于治疗重症患者的方法和药剂 | |
Jayat et al. | Design of Beta-Lactoglobulins with Increased Affinities for Retinol and Palmitic Acid | |
CS256710B1 (en) | Method of albumin extraction from cohne fraction 4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GRIFOLS, S.A., SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JORQUERA NIETO, JUAN IGNACIO;ORTIZ FERNANDEZ, ANA MARIA;COSTA RIEROLA, MONTSERRAT;SIGNING DATES FROM 20150413 TO 20150423;REEL/FRAME:035737/0922 |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |